Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Andrew J Yee"'
Autor:
Andrew J. Yee
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/5f5b2f3913084dd3abb0b1f7373387e3
Autor:
Ethan Katznelson, Michael Jerosch-Herold, Sarah A. M. Cuddy, Olivier F. Clerc, Dominik C. Benz, Alexandra Taylor, Shivani Rao, Marie Foley Kijewski, Ronglih Liao, Heather Landau, Andrew J. Yee, Frederick L. Ruberg, Marcelo F. Di Carli, Rodney H. Falk, Raymond Y. Kwong, Sharmila Dorbala
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundCardiac systolic dysfunction is a poor prognostic marker in light-chain (AL) cardiomyopathy, a primary interstitial disorder; however, its pathogenesis is poorly understood.PurposeThis study aims to analyze the effects of extracellular volu
Externí odkaz:
https://doaj.org/article/a5107d2f7aab4c2988e054c8f21cbba7
Autor:
Ayman Al Jurdi, MD, Abraham Cohen Bucay, MD, Leonardo V. Riella, MD, PhD, Andrew J. Yee, MD, Cherif Abdelmalek, MD, Veronica Klepeis, MD, PhD, Shoko Kimura, MD, PhD, Kassem Safa, MD
Publikováno v:
Transplantation Direct, Vol 10, Iss 5, p e1616 (2024)
Externí odkaz:
https://doaj.org/article/9a18f4f7a2244c139e99dadc047416c5
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 421-422 (2024)
Externí odkaz:
https://doaj.org/article/1020bc2c9ff94a07863ff8f815d54c24
Autor:
Clifton C. Mo, Andrew J. Yee, Shonali Midha, Monique A. Hartley‐Brown, Omar Nadeem, Elizabeth K. O'Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach, Paul G. Richardson
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 792-810 (2023)
Abstract Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nu
Externí odkaz:
https://doaj.org/article/df6d5d22d8aa4c3088dccaac48019fd0
Autor:
Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 10, Pp 1-12 (2022)
Abstract Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias. Granulocyt
Externí odkaz:
https://doaj.org/article/3228817cf75c47368f94792a61f6aa4d
Autor:
Sandy W. Wong, Noffar Bar, María Victoria Mateos, Paz Ribas, Markus Hansson, Laura Paris, Craig Hofmeister, Paula Rodriguez-Otero, Maria Aranzazu Bermúdez, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas, Claudio Cerchione, Javier de la Rubia, Albert Oriol, Barbara Ferstl, Britta Besemer, Jinjie Chen, Alexander Chung, Isaac W. Boss, Allison Gaudy, Shaoyi LI, Kevin Hsu, Colin Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano Jose Costa
Publikováno v:
HemaSphere, Vol 7, p e1220745 (2023)
Externí odkaz:
https://doaj.org/article/2230834f84a148e3a0a1059145ec090f
Autor:
Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little, Noopur S. Raje
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 6, Pp 1-11 (2022)
Abstract A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eve
Externí odkaz:
https://doaj.org/article/0238267280cc4458be0fc24b8b97fe2d
Autor:
Yael N. Shapiro, Jeffrey M. Peppercorn, Andrew J. Yee, Andrew R. Branagan, Noopur S. Raje, Elizabeth K. O’ Donnell
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 10, Pp 1-9 (2021)
Abstract As the prognosis for multiple myeloma (MM) has significantly improved and patients remain on therapy longer, there is a need for supportive care interventions to optimize patient quality of life (QOL) and functional status over the course of
Externí odkaz:
https://doaj.org/article/84eaa9d15b9541d8ad536fd902621277
Autor:
Andrew J. Yee
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone
Externí odkaz:
https://doaj.org/article/3581cfe2d0a14b92a238766458dbfe95